Literature DB >> 12472984

Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia.

X S Ren1, L E Kazis, A F Lee, A Hamed, Y H Huang, F Cunningham, D R Miller.   

Abstract

BACKGROUND: Schizophrenia, one of the leading causes of disability, contributes substantially to the use of medical and mental health services. The treatment of schizophrenia is therefore particularly important to reduce deficits across a large number of neurocognitive domains.
OBJECTIVE: To describe the prescription (e.g. initiation and switching) patterns of atypical antipsychotic agents and examine the extent to which patient sociodemographic and clinical characteristics are associated with the prescription patterns of atypical antipsychotics among patients with schizophrenia.
METHODS: Using unique data sources from the Veterans Health Administration (VA), the study identified 89 107 patients with schizophrenia based on at least one inpatient or more than or equal to two outpatients' ICD-9-CM codes (> or =7 days apart). We defined a prior 6-month (1/1/99 to 6/30/99) and a post 6-month (7/1/99 to 12/31/99) period to describe patterns of initiation and switching of atypical antipsychotics.
RESULTS: Only a small number of patients were on clozapine (1.8%) and quetiapine (1.4%). More patients were prescribed olanzapine (23%) than risperidone (20%) (P < 0.001). Compared with patients who were on risperidone, those who were on olanzapine were younger (P < 0.001), more likely Hispanic (P < 0.001), more likely married (P < 0.05), had more service-connected disability (P < 0.001), had fewer numbers of physical comorbidities (P < 0.001), and a lower body mass index (BMI) (P < 0.05).
CONCLUSION: Olanzapine and risperidone appear to be prescribed to patients with different sociodemographic and clinical characteristics. Future research needs to explore the reasons for those differences.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12472984     DOI: 10.1046/j.1365-2710.2002.00443.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  12 in total

1.  Patterns of clozapine prescribing in a mental health service in New Zealand.

Authors:  Jeff Harrison; Minna Janlöv; Amanda J Wheeler
Journal:  Pharm World Sci       Date:  2010-06-06

2.  The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology.

Authors:  Marc De Hert; Mauro Mauri; Ken Shaw; Tilman Wetterling; Adam Doble; Agnès Giudicelli; Bruno Falissard
Journal:  Int J Methods Psychiatr Res       Date:  2010-12       Impact factor: 4.035

3.  Oral antipsychotic prescribing and association with neighbourhood-level socioeconomic status: analysis of time trend of routine primary care data in England, 2011-2016.

Authors:  Kurt Buhagiar; Mustafa Ghafouri; Mrinalini Dey
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-10-19       Impact factor: 4.328

4.  Choice of atypical antipsychotic therapy for patients with schizophrenia: An analysis of a medicaid population.

Authors:  Gordon G Liu; Shawn X Sun; Dale B Christensen; Zhongyun Zhao
Journal:  Curr Ther Res Clin Exp       Date:  2005-09

5.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

6.  Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.

Authors:  Hong Liu-Seifert; Haya Ascher-Svanum; Olawale Osuntokun; Kai Yu Jen; Juan Carlos Gomez
Journal:  BMC Psychiatry       Date:  2011-05-17       Impact factor: 3.630

7.  Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.

Authors:  Xiaoning He; Jing Wu; Yawen Jiang; Li Liu; Wenyu Ye; Haibo Xue; William Montgomery
Journal:  BMC Health Serv Res       Date:  2015-04-09       Impact factor: 2.655

8.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07

9.  Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Jonathan P Lacro; Christian R Dolder; Xiaomei Peng
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

10.  An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration.

Authors:  Xinhua S Ren; Shirley Qian; Lewis E Kazis
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.